How to buy Compumedics shares | A$0.4
Own Compumedics shares in just a few minutes.
Compumedics Limited is a medical devices business based in Australia. Compumedics shares (CMP) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Its last market close was $0.4 – an increase of 8.11% over the previous week. Compumedics has a trailing 12-month revenue of around $35.1 million.
How to buy shares in Compumedics
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Compumedics. Find the share by name or ticker symbol: CMP. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Compumedics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price of $0.4, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check in on your investment. Congratulations, you own a part of Compumedics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
How has coronavirus impacted Compumedics's share price?
Since the stock market crash in March caused by coronavirus, Compumedics's share price has had significant negative movement.
Its last market close was $0.4, which is 50.00% down on its pre-crash value of $0.8 and 60.00% up on the lowest point reached during the March crash when the shares fell as low as $0.25.
If you had bought $1,000 worth of Compumedics shares at the start of February 2020, those shares would have been worth $453.13 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $625.00.
Compumedics share priceUse our graph to track the performance of CMP stocks over time.
Compumedics shares at a glance
|Latest market close||AUDA$0.4|
|52-week range||AUDA$0.25 - AUDA$0.96|
|50-day moving average||AUDA$0.4165|
|200-day moving average||AUDA$0.4386|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||AUDA$0.019|
Standard brokerage - Australian shares
Share Trading Account Offer
Competitive broker fees on Australian and international shares
- Brokerage - AU shares: From AUD 5 or 0.05%
- Brokerage - US shares: USD 0
- Sign-up process: Instant
- Support - After hours: Yes
Important: Share trading carries risk of capital loss.
Compare share trading platforms
Is it a good time to buy Compumedics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Compumedics price performance over time
|1 week (2020-09-22)||8.11%|
|1 month (2020-08-28)||-5.88%|
|3 months (2020-06-29)||-5.88%|
|6 months (2020-03-27)||33.33%|
|1 year (2019-09-27)||-33.33%|
|2 years (2018-09-28)||-11.11%|
|3 years (2017-09-28)||9.59%|
|5 years (2015-09-29)||50.94%|
Is Compumedics under- or over-valued?
Valuing Compumedics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Compumedics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Compumedics's P/E ratio
Compumedics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 23x. In other words, Compumedics shares trade at around 23x recent earnings.
That's relatively low compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Compumedics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.3 million.
The EBITDA is a measure of a Compumedics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$35.1 million|
|Operating margin TTM||1.45%|
|Gross profit TTM||$18 million|
|Return on assets TTM||0.86%|
|Return on equity TTM||-23.78%|
|Market capitalisation||$71.4 million|
TTM: trailing 12 months
Compumedics share dividends
We're not expecting Compumedics to pay a dividend over the next 12 months.
Compumedics share price volatility
Over the last 12 months, Compumedics's shares have ranged in value from as little as $0.25 up to $0.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Compumedics's is 0.8946. This would suggest that Compumedics's shares are less volatile than average (for this exchange).
Compumedics Limited researches, develops, manufactures, sells, and distributes medical devices in Australia, the Asia Pacific, the Americas, Europe, and the Middle East. It provides sleep diagnostics products, including Grael 4K PSG:EEG amplifiers; Somté PSG; Siesta 802, an ambulatory recording device; Grael PSG; and Somté, an investigative tool. The company also provides neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG:EEG amplifiers; Grael 4K-EEG amplifiers; Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Xegis Forte EMG/EP; and Xegis G:NEO 2 Channel EMG/EP systems. In addition, it offers software products, such as Profusion Sleep software suite; Profusion EEG Software; ProFusion neXus 360, a Web-based patient data and lab management system that provides integrated hardware and software solutions for sleep and neurology clinics; Multi-Modal Neuroimaging Suite; Profusion neXus Laboratory Management System to optimize administrative and operational workflow needs of diagnostic and research laboratories; Profusion neXus Scheduler for planning for staff and time; and Digital Video, a plug-in software module to add synchronized digital video capabilities to sleep and EEG systems, as well as ECG Free, Profusion Plus, Siesta extended battery pack, and summit IP products. Further, the company provides magnetoencephalography systems; brain research technologies; pharmaceutical clinical trials and research services; accessories; and a range of consumables and supplies for diagnostic and research solutions. The company was founded in 1987 and is headquartered in Abbotsford, Australia. Compumedics Limited is a subsidiary of D & DJ Burton Holdings Pty Ltd.
Frequently asked questions
Ask an Expert